Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.

Abstract

Treatment of patients with ANCA-associated vasculitis (AAV) and severe renal involvement is not established. We describe outcomes in response to rituximab (RTX) versus cyclophosphamide (CYC) and plasma exchange (PLEX). A retrospective cohort study of MPO- or PR3-ANCA-positive patients with AAV (MPA and GPA) and severe kidney disease (eGFR <30 ml/min per 1.73 m²). Remission, relapse, ESKD and death after remission-induction with CYC or RTX, with or without the use of PLEX, were compared. Of 467 patients with active renal involvement, 251 had severe kidney disease. Patients received CYC (<i>n</i>=161) or RTX (<i>n</i>=64) for remission-induction, and 51 were also treated with PLEX. Predictors for ESKD and/or death at 18 months were eGFR <15 ml/min per 1.73 m² at diagnosis (IRR 3.09 [95% CI 1.49 to 6.40], <i>P</i>=0.002), renal recovery (IRR 0.27 [95% CI 0.12 to 0.64], <i>P</i>=0.003) and renal remission at 6 months (IRR 0.40 [95% CI 0.18 to 0.90], <i>P</i>=0.027). RTX was comparable to CYC in remission-induction (BVAS/WG=0) at 6 months (IRR 1.37 [95% CI 0.91 to 2.08], <i>P</i>=0.132). Addition of PLEX showed no benefit on remission-induction at 6 months (IRR 0.73 [95% CI 0.44 to 1.22], <i>P</i>=0.230), the rate of ESKD and/or death at 18 months (IRR 1.05 [95% CI 0.51 to 2.18], <i>P</i>=0.891), progression to ESKD (IRR 1.06 [95% CI 0.50 to 2.25], <i>P</i>=0.887), and survival at 24 months (IRR 0.54 [95% CI 0.16 to 1.85], <i>P</i>=0.330). The apparent benefits and risks of using CYC or RTX for the treatment of patients with AAV and severe kidney disease are balanced. The addition of PLEX to standard remission-induction therapy showed no benefit in our cohort. A randomized controlled trial is the only satisfactory means to evaluate efficacy of remission-induction treatments in AAV with severe renal involvement.